- Home
- USIO vs AKTX Comparison
USIO vs AKTX Comparison
Compare USIO & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USIO
- AKTX
- Stock Information
- Founded
- USIO 1998
- AKTX N/A
- Country
- USIO United States
- AKTX United States
- Employees
- USIO N/A
- AKTX N/A
- Industry
- USIO Investment Bankers/Brokers/Service
- AKTX Biotechnology: Pharmaceutical Preparations
- Sector
- USIO Finance
- AKTX Health Care
- Exchange
- USIO Nasdaq
- AKTX Nasdaq
- Market Cap
- USIO 37.1M
- AKTX 41.8M
- IPO Year
- USIO N/A
- AKTX N/A
- Fundamental
- Price
- USIO $1.44
- AKTX $1.12
- Analyst Decision
- USIO Strong Buy
- AKTX
- Analyst Count
- USIO 1
- AKTX 0
- Target Price
- USIO $4.00
- AKTX N/A
- AVG Volume (30 Days)
- USIO 59.9K
- AKTX 25.4K
- Earning Date
- USIO 08-13-2025
- AKTX 08-18-2025
- Dividend Yield
- USIO N/A
- AKTX N/A
- EPS Growth
- USIO N/A
- AKTX N/A
- EPS
- USIO 0.12
- AKTX N/A
- Revenue
- USIO $83,970,504.00
- AKTX N/A
- Revenue This Year
- USIO $16.33
- AKTX N/A
- Revenue Next Year
- USIO $14.56
- AKTX N/A
- P/E Ratio
- USIO $12.04
- AKTX N/A
- Revenue Growth
- USIO 0.46
- AKTX N/A
- 52 Week Low
- USIO $1.24
- AKTX $0.85
- 52 Week High
- USIO $2.92
- AKTX $4.40
- Technical
- Relative Strength Index (RSI)
- USIO 52.76
- AKTX 47.22
- Support Level
- USIO $1.38
- AKTX $1.08
- Resistance Level
- USIO $1.43
- AKTX $1.25
- Average True Range (ATR)
- USIO 0.05
- AKTX 0.08
- MACD
- USIO 0.01
- AKTX -0.01
- Stochastic Oscillator
- USIO 50.00
- AKTX 39.71
About USIO Usio Inc.
Usio Inc is a United States-based company that provides integrated electronic payment services, including credit and debit card-based processing services and transaction processing via the Automated Clearing House, or ACH network to billers and retailers. The Company also has an additional wholly-owned subsidiary, which is the entity for Output Solutions operations.
About AKTX Akari Therapeutics plc ADS
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.